{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T14:15:00Z","timestamp":1770819300797,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"DOI":"10.13039\/100006034","name":"University of Southern California","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006034","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>High-risk non-muscle-invasive bladder cancer (NMIBC) is most commonly treated with Bacillus Calmette\u2013Gu\u00e9rin (BCG) as first-line therapy. However, in light of the ongoing BCG shortage in the United States, a\u00a0significant need exists for alternative treatment options, both in the upfront setting as well as for patients with BCG-refractory disease. While radical cystectomy remains the gold standard for patients with BCG-refractory disease, many patients are unfit or unwilling to undergo this procedure. Several new agents, many with novel mechanisms of action, have been approved or are actively being investigated in this setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>Articles were chosen for review based on expert knowledge of the literature as well as on PubMed literature searches for the topics of focus. Appropriate articles were selected for inclusion by reviewing article titles, abstracts, and full texts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>There is ample evidence for emerging therapies in BCG-refractory NMIBC including systemic immunotherapy and various intravesical options, such as chemotherapy, gene therapy, and novel drug delivery systems. Radical cystectomy, however, remains the gold standard. Response rates and duration of response vary across treatment modalities, with complete response rates at any time ranging from 41% to 82%. Radical cystectomy should still be recommended to patients with high-risk features given the risks of recurrence, progression, upstaging, and occult lymph node metastases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>While radical cystectomy remains the standard of care for patients with BCG-refractory disease, many patients are unable or unwilling to undergo the procedure. Several novel therapies have been recently approved or are currently being investigated with overall promising early results.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00120-025-02625-2","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T10:35:41Z","timestamp":1750674941000},"page":"162-170","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Modern management of BCG-refractory non-muscle-invasive urothelial carcinoma of the urinary bladder","Moderne Behandlung des BCG-refrakt\u00e4ren nichtmuskelinvasiven Urothelkarzinoms der Harnblase"],"prefix":"10.1007","volume":"65","author":[{"given":"Domenique","family":"Escobar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chirag","family":"Doshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mazyar","family":"Zahir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siamak","family":"Daneshmand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,23]]},"reference":[{"issue":"1","key":"2625_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel\u00a0RL, Giaquinto\u00a0AN, Jemal\u00a0A (2024) Cancer statistics, 2024. CA A Cancer J Clinicians 74(1):12\u201349. https:\/\/doi.org\/10.3322\/caac.21820","journal-title":"CA A Cancer J Clinicians"},{"issue":"1","key":"2625_CR2","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk\u00a0M, Burger\u00a0M, Capoun\u00a0O et\u00a0al (2022) European association of urology guidelines on non\u2013muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol 81(1):75\u201394. https:\/\/doi.org\/10.1016\/j.eururo.2021.08.010","journal-title":"Eur Urol"},{"key":"2625_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076743","author":"A Lopez-Beltran","year":"2024","unstructured":"Lopez-Beltran\u00a0A, Cookson\u00a0MS, Guercio\u00a0BJ, Cheng\u00a0L (2024) Advances in diagnosis and treatment of bladder cancer. BMJ. https:\/\/doi.org\/10.1136\/bmj-2023-076743","journal-title":"BMJ"},{"issue":"3","key":"2625_CR4","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/cncr.30392","volume":"123","author":"VT Packiam","year":"2017","unstructured":"Packiam\u00a0VT, Johnson\u00a0SC, Steinberg\u00a0GD (2017) Non\u2013muscle-invasive bladder cancer: Intravesical treatments beyond Bacille C almette- G u\u00e9rin. Cancer 123(3):390\u2013400. https:\/\/doi.org\/10.1002\/cncr.30392","journal-title":"Cancer"},{"issue":"5","key":"2625_CR5","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","volume":"168","author":"RJ Sylvester","year":"2002","unstructured":"Sylvester\u00a0RJ, Van Der Meijden\u00a0APM, Lamm\u00a0DL (2002) Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a\u00a0meta-analysis of the published results of randomized clinical trials. J\u00a0Urol 168(5):1964\u20131970. https:\/\/doi.org\/10.1016\/S0022-5347(05)64273-5","journal-title":"J Urol"},{"issue":"1","key":"2625_CR6","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","volume":"69","author":"S Cambier","year":"2016","unstructured":"Cambier\u00a0S, Sylvester\u00a0RJ, Collette\u00a0L et\u00a0al (2016) EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non\u2013muscle-invasive stage Ta\u2013T1 Urothelial bladder cancer patients treated with 1\u20133 years of maintenance bacillus Calmette-Gu\u00e9rin. Eur Urol 69(1):60\u201369. https:\/\/doi.org\/10.1016\/j.eururo.2015.06.045","journal-title":"Eur Urol"},{"key":"2625_CR7","unstructured":"(2018) BCG-unresponsive Nonmuscle invasive bladder cancer: developing drug and biological products for treatment. United States food and drug administration. https:\/\/www.fda.gov\/media\/101468\/download"},{"issue":"6","key":"2625_CR8","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.eururo.2018.02.014","volume":"73","author":"MGK Cumberbatch","year":"2018","unstructured":"Cumberbatch\u00a0MGK, Foerster\u00a0B, Catto\u00a0JWF et\u00a0al (2018) Repeat Transurethral resection in non\u2013muscle-invasive bladder cancer: a\u00a0systematic review. Eur Urol 73(6):925\u2013933. https:\/\/doi.org\/10.1016\/j.eururo.2018.02.014","journal-title":"Eur Urol"},{"issue":"5","key":"2625_CR9","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1097\/JU.0000000000002848","volume":"208","author":"IM McElree","year":"2022","unstructured":"McElree\u00a0IM, Packiam\u00a0VT, Steinberg\u00a0RL et\u00a0al (2022) Sequential Intravesical Valrubicin and Docetaxel for the salvage treatment of non\u2013muscle-invasive bladder cancer. J\u00a0Urol 208(5):969\u2013977. https:\/\/doi.org\/10.1097\/JU.0000000000002848","journal-title":"J Urol"},{"issue":"3","key":"2625_CR10","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.euo.2020.02.006","volume":"3","author":"AM Kamat","year":"2020","unstructured":"Kamat\u00a0AM, Lerner\u00a0SP, O\u2019Donnell\u00a0M et\u00a0al (2020) Evidence-based assessment of current and emerging bladder-sparing therapies for non\u2013muscle-invasive bladder cancer after bacillus Calmette-Guerin therapy: a\u00a0systematic review and meta-analysis. Eur Urol Oncol 3(3):318\u2013340. https:\/\/doi.org\/10.1016\/j.euo.2020.02.006","journal-title":"Eur Urol Oncol"},{"issue":"7","key":"2625_CR11","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","volume":"22","author":"AV Balar","year":"2021","unstructured":"Balar\u00a0AV, Kamat\u00a0AM, Kulkarni\u00a0GS et\u00a0al (2021) Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase\u00a02\u00a0study. Lancet Oncol 22(7):919\u2013930. https:\/\/doi.org\/10.1016\/S1470-2045(21)00147-9","journal-title":"Lancet Oncol"},{"issue":"5","key":"2625_CR12","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1097\/JU.0000000000000688","volume":"203","author":"RL Steinberg","year":"2020","unstructured":"Steinberg\u00a0RL, Thomas\u00a0LJ, Brooks\u00a0N et\u00a0al (2020) Multi-institution evaluation of sequential Gemcitabine and Docetaxel as rescue therapy for Nonmuscle invasive bladder cancer. J\u00a0Urol 203(5):902\u2013909. https:\/\/doi.org\/10.1097\/JU.0000000000000688","journal-title":"J Urol"},{"issue":"3","key":"2625_CR13","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1097\/JU.0000000000002740","volume":"208","author":"IM McElree","year":"2022","unstructured":"McElree\u00a0IM, Steinberg\u00a0RL, Martin\u00a0AC et\u00a0al (2022) Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Gu\u00e9rin-Na\u00efve high-risk Nonmuscle-invasive bladder cancer. J\u00a0Urol 208(3):589\u2013599. https:\/\/doi.org\/10.1097\/JU.0000000000002740","journal-title":"J Urol"},{"issue":"8","key":"2625_CR14","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1002\/cncr.24914","volume":"116","author":"G Di Lorenzo","year":"2010","unstructured":"Di Lorenzo\u00a0G, Perdon\u00e0\u00a0S, Damiano\u00a0R et\u00a0al (2010) Gemcitabine versus bacille Calmette-Gu\u00e9rin after initial bacille Calmette-Gu\u00e9rin failure in non-muscle-invasive bladder cancer: a\u00a0multicenter prospective randomized trial. Cancer 116(8):1893\u20131900. https:\/\/doi.org\/10.1002\/cncr.24914","journal-title":"Cancer"},{"issue":"4","key":"2625_CR15","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s40265-023-01846-z","volume":"83","author":"A Lee","year":"2023","unstructured":"Lee\u00a0A (2023) Nadofaragene Firadenovec: first approval. Drugs 83(4):353\u2013357. https:\/\/doi.org\/10.1007\/s40265-023-01846-z","journal-title":"Drugs."},{"issue":"1","key":"2625_CR16","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","volume":"22","author":"SA Boorjian","year":"2021","unstructured":"Boorjian\u00a0SA, Alemozaffar\u00a0M, Konety\u00a0BR et\u00a0al (2021) Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a\u00a0single-arm, open-label, repeat-dose clinical trial. Lancet Oncol 22(1):107\u2013117. https:\/\/doi.org\/10.1016\/S1470-2045(20)30540-4","journal-title":"Lancet Oncol"},{"issue":"1","key":"2625_CR17","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1097\/JU.0000000000004020","volume":"212","author":"VM Narayan","year":"2024","unstructured":"Narayan\u00a0VM, Boorjian\u00a0SA, Alemozaffar\u00a0M et\u00a0al (2024) Efficacy of Intravesical Nadofaragene Firadenovec for patients with bacillus Calmette-Gu\u00e9rin\u2013unresponsive Nonmuscle-invasive bladder cancer: 5\u2011year follow-up from a\u00a0phase\u00a03 trial. J\u00a0Urol 212(1):74\u201386. https:\/\/doi.org\/10.1097\/JU.0000000000004020","journal-title":"J Urol"},{"issue":"16","key":"2625_CR18","doi-asserted-by":"publisher","first-page":"4508","DOI":"10.1200\/JCO.2022.40.16_suppl.4508","volume":"40","author":"K Chamie","year":"2022","unstructured":"Chamie\u00a0K, Chang\u00a0SS, Gonzalgo\u00a0M et\u00a0al (2022) Final clinical results of pivotal trial of IL-15R\u03b1Fc superagonist N\u2011803 with BCG in BCG-unresponsive CIS and papillary nonmuscle-invasive bladder cancer (NMIBC). JCO 40(16):4508\u20134508. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.4508","journal-title":"JCO"},{"key":"2625_CR19","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200167","author":"K Chamie","year":"2023","unstructured":"Chamie\u00a0K, Chang\u00a0SS, Kramolowsky\u00a0E et\u00a0al (2023) IL-15 Superagonist NAI in BCG-Unresponsive Non\u2013Muscle-Invasive Bladder Cancer. NEJM Evidence. https:\/\/doi.org\/10.1056\/EVIDoa2200167","journal-title":"NEJM Evidence"},{"issue":"7","key":"2625_CR20","doi-asserted-by":"publisher","first-page":"344.e1","DOI":"10.1016\/j.urolonc.2022.02.009","volume":"40","author":"S Daneshmand","year":"2022","unstructured":"Daneshmand\u00a0S, Brummelhuis\u00a0ISG, Pohar\u00a0KS et\u00a0al (2022) The safety, tolerability, and efficacy of a\u00a0neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: a\u00a0phase\u00a0I trial. Urol Oncol Seminars Orig Investig 40(7):344.e1\u2013344.e9. https:\/\/doi.org\/10.1016\/j.urolonc.2022.02.009","journal-title":"Urol Oncol Seminars Orig Investig"},{"key":"2625_CR21","unstructured":"Van der Heijden M, Klaassen Z ESMO 2024: TAR-200 +\/- Cetrelimab and Cetrelimab alone in patients with BCG-unresponsive high-risk NMIBC: updated results from sunRIse\u20111. https:\/\/www.urotoday.com\/conference-highlights\/esmo-2024\/esmo-2024-bladder-cancer\/154852-esmo-2024-tar-200-cetrelimab-and-cetrelimab-alone-in-patients-with-bcg-unresponsive-high-risk-nmibc-updated-results-from-sunrise-1.html"},{"key":"2625_CR22","doi-asserted-by":"publisher","first-page":"S1343","DOI":"10.1016\/j.annonc.2023.10.110","volume":"34","author":"A Vilaseca","year":"2023","unstructured":"Vilaseca\u00a0A, Jayram\u00a0G, Raventos\u00a0C et\u00a0al (2023) LBA104 First safety and efficacy results of the TAR-210 erdafitinib (erda) intravesical delivery system in patients (pts) with non\u2013muscle-invasive bladder cancer (NMIBC) with select FGFR alterations (alt). Ann Oncol 34:S1343. https:\/\/doi.org\/10.1016\/j.annonc.2023.10.110","journal-title":"Ann Oncol"},{"key":"2625_CR23","doi-asserted-by":"publisher","DOI":"10.1097\/01.JU.0001015816.87470.c9.02","author":"MD Tyson","year":"2024","unstructured":"Tyson\u00a0MD, Uchio\u00a0E, Nam\u00a0JK et\u00a0al (2024) P2-02 Pivotal results from BOND-003: A\u00a0phase 3, single-arm study of intravesical cretostimogene grenadenorepvec for the treatment of high risk, bcg-unresponsive non-muscle invasive bladder cancer with carcinoma in situ. J\u00a0Urol. https:\/\/doi.org\/10.1097\/01.JU.0001015816.87470.c9.02","journal-title":"J Urol"},{"key":"2625_CR24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.5_suppl.TPS901","author":"T Bivalacqua","year":"2025","unstructured":"Bivalacqua\u00a0T, Daneshmand\u00a0S, Shore\u00a0ND, Joshi\u00a0S, Dinney\u00a0CPN (2025) CORE-008: a\u00a0phase\u00a02, multi-arm, multi-cohort, open-label study to evaluate intravesical cretostimogene grenadenorepvec in participants with high-risk non-muscle invasive bladder cancer. JCO. https:\/\/doi.org\/10.1200\/JCO.2025.43.5_suppl.TPS901","journal-title":"JCO"},{"key":"2625_CR25","doi-asserted-by":"publisher","DOI":"10.1097\/01.JU.0001015816.87470.c9.08","author":"S Kalota","year":"2024","unstructured":"Kalota\u00a0S, Joshi\u00a0S, Bui\u00a0M et\u00a0al (2024) P2-08 legend: A\u00a0phase 1\/2 study of EG-70 (detalimogene voraplasmid), A\u00a0novel, non-viral intravesical gene therapy for patients with bcg-unresponsive non-muscle invasive bladder cancer with carcinoma in situ (CIS). J\u00a0Urol. https:\/\/doi.org\/10.1097\/01.JU.0001015816.87470.c9.08","journal-title":"J Urol"},{"key":"2625_CR26","doi-asserted-by":"crossref","unstructured":"Mazzarella B, Chavarriaga J SUO 2024: ADVANCED-2: phase\u00a02 open-label study to evaluate safety and anti-tumor activity of Intravesical instillation of TARA-002 in adults with high-grade non-muscle invasive bladder cancer. https:\/\/www.urotoday.com\/conference-highlights\/suo-2024\/suo-2024-bladder-cancer\/156746-suo-2024-advanced-2-phase-2-open-label-study-to-evaluate-safety-and-anti-tumor-activity-of-intravesical-instillation-of-tara-002-in-adults-with-high-grade-non-muscle-invasive-bladder-cancer.html","DOI":"10.1016\/j.urolonc.2024.12.122"},{"issue":"2","key":"2625_CR27","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/bju.16509","volume":"135","author":"JI Taylor","year":"2025","unstructured":"Taylor\u00a0JI, Kamat\u00a0AM, O\u2019Donnell\u00a0MA et\u00a0al (2025) Long-term outcomes of bladder-sparing therapy vs radical cystectomy in BCG-unresponsive non-muscle-invasive bladder cancer. BJU Int 135(2):260\u2013268. https:\/\/doi.org\/10.1111\/bju.16509","journal-title":"BJU Int"},{"issue":"2","key":"2625_CR28","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.ucl.2013.01.003","volume":"40","author":"S Daneshmand","year":"2013","unstructured":"Daneshmand\u00a0S (2013) Determining the role of Cystectomy for high-grade T1 Urothelial carcinoma. Urol Clin N Am 40(2):233\u2013247. https:\/\/doi.org\/10.1016\/j.ucl.2013.01.003","journal-title":"Urol Clin N Am"},{"issue":"11","key":"2625_CR29","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1007\/s10147-021-01988-8","volume":"26","author":"K Iida","year":"2021","unstructured":"Iida\u00a0K, Miyake\u00a0M, Murakami\u00a0K et\u00a0al (2021) Bacillus Calmette-Gu\u00e9rin-unresponsive non-muscle invasive bladder cancer outcomes in patients without radical cystectomy. Int J Clin Oncol 26(11):2104\u20132112. https:\/\/doi.org\/10.1007\/s10147-021-01988-8","journal-title":"Int J Clin Oncol"},{"issue":"4","key":"2625_CR30","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1097\/JU.0000000000003846","volume":"211","author":"JM Holzbeierlein","year":"2024","unstructured":"Holzbeierlein\u00a0JM, Bixler\u00a0BR, Buckley\u00a0DI et\u00a0al (2024) Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA\/SUO Guideline: 2024 Amendment. J\u00a0Urol 211(4):533\u2013538. https:\/\/doi.org\/10.1097\/JU.0000000000003846","journal-title":"J Urol"},{"key":"2625_CR31","unstructured":"(2025) NCCN clinical practice guidelines in oncology (NCCN guidelines\u00ae): bladder cancer. Version 7.2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf"},{"issue":"3","key":"2625_CR32","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11912-019-0772-8","volume":"21","author":"JT Matulay","year":"2019","unstructured":"Matulay\u00a0JT, Narayan\u00a0VM, Kamat\u00a0AM (2019) Clinical and genomic considerations for variant histology in bladder cancer. Curr Oncol Rep 21(3):23. https:\/\/doi.org\/10.1007\/s11912-019-0772-8","journal-title":"Curr Oncol Rep"}],"container-title":["Die Urologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-025-02625-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-025-02625-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-025-02625-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T13:29:17Z","timestamp":1770816557000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-025-02625-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,23]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2625"],"URL":"https:\/\/doi.org\/10.1007\/s00120-025-02625-2","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"value":"2731-7064","type":"print"},{"value":"2731-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,23]]},"assertion":[{"value":"12 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"D.\u00a0Escobar, C.\u00a0Doshi, M.\u00a0Zahir and S.\u00a0Daneshmand declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}